Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Recent performance snapshot
Novo Nordisk (CPSE:NOVO B) has seen mixed share performance, with the stock down 0.7% over the past day and 2.8% over the past week, but up 8.1% over the past 3 months.
Over longer periods the picture is more challenging, with the stock down over the past month, year to date, and past year, while still showing a gain over the past 5 years. This provides important context before looking at fundamentals.
See our latest analysis for Novo Nordisk.
At a share price of DKK270.0, Novo Nordisk’s 1 month share price return is down 7%, while its 1 year total shareholder return is down 46%, pointing to fading momentum after a stronger 5 year total shareholder return of 16%.
If you are comparing Novo Nordisk with other healthcare opportunities, it could be worth scanning for ideas in fast growing healthcare and biotech using the 132 healthcare AI stocks
With Novo Nordisk now carrying a DKK270.0 share price after a tough year and some slowing earnings growth, the key question is simple: is this a reset that leaves potential upside on the table, or is the market already pricing in future growth?
Most Popular Narrative: 33.8% Undervalued
Against the last close of DKK270.0, the most followed narrative on Novo Nordisk sees a fair value of DKK407.77, implying a sizeable valuation gap that the market has not closed.
Bottom Line: Novo Nordisk is transitioning from a high-growth momentum stock to a mature dominant player fighting off rivals. It remains a high-quality business, but the days of effortless earnings beats are likely behind us.
The valuation hinges on how long high margins can be maintained while earnings, revenue and future profit multiples adjust to a slower growth phase and heavier competition.
Result: Fair Value of DKK407.77 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this depends on key risks, including potential margin pressure from lower priced China sales and higher costs tied to oral Wegovy production and capacity.
Find out about the key risks to this Novo Nordisk narrative.
Next Steps
With sentiment clearly split between risk and reward, it helps to see the full picture quickly and decide where you stand using the 3 key rewards and 3 important warning signs.
Looking for more investment ideas?
If you stop with just one stock, you risk missing other opportunities that could fit your goals even better. Keep your watchlist open and active.